PT1755674E - Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento - Google Patents

Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento Download PDF

Info

Publication number
PT1755674E
PT1755674E PT57799249T PT05779924T PT1755674E PT 1755674 E PT1755674 E PT 1755674E PT 57799249 T PT57799249 T PT 57799249T PT 05779924 T PT05779924 T PT 05779924T PT 1755674 E PT1755674 E PT 1755674E
Authority
PT
Portugal
Prior art keywords
allograft
prolongation
survival
complement activity
inhibiting complement
Prior art date
Application number
PT57799249T
Other languages
English (en)
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385551&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1755674(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of PT1755674E publication Critical patent/PT1755674E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT57799249T 2004-05-14 2005-05-16 Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento PT1755674E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57144404P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
PT1755674E true PT1755674E (pt) 2015-02-05

Family

ID=35385551

Family Applications (1)

Application Number Title Priority Date Filing Date
PT57799249T PT1755674E (pt) 2004-05-14 2005-05-16 Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento

Country Status (14)

Country Link
US (3) US20090028850A1 (pt)
EP (4) EP2338511A3 (pt)
JP (3) JP5161567B2 (pt)
AU (1) AU2005244012C1 (pt)
CA (1) CA2566716C (pt)
DK (1) DK1755674T3 (pt)
ES (1) ES2528362T3 (pt)
HK (3) HK1101962A1 (pt)
IL (2) IL179240A (pt)
NZ (1) NZ551308A (pt)
PL (1) PL1755674T3 (pt)
PT (1) PT1755674E (pt)
SI (1) SI1755674T1 (pt)
WO (1) WO2005110481A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
EP1988882B1 (en) * 2006-03-02 2014-12-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
EP3167888B1 (en) 2006-03-15 2024-05-01 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
HUE026042T2 (en) 2006-10-10 2016-05-30 Regenesance B V Complement inhibition for improved nerve regeneration
KR20110094029A (ko) * 2008-11-10 2011-08-19 알렉시온 파마슈티칼스, 인코포레이티드 보체-관련된 장애를 치료하는 방법 및 조성물
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
WO2011003098A1 (en) * 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
DK2884999T3 (da) 2012-08-20 2021-01-04 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fremgangsmåde og sammensætninger til cellulær immunterapi
WO2015021166A2 (en) 2013-08-07 2015-02-12 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome biomarker proteins
EP3033093A1 (en) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
EP3207121B1 (en) 2014-10-15 2019-02-27 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
EP3288586A1 (en) * 2015-05-01 2018-03-07 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
JP7102353B2 (ja) 2016-06-14 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃ５抗体及びそれらの使用
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞***移植调控补体活化作用的体系
WO2024121811A1 (en) * 2022-12-08 2024-06-13 Novmetapharma Co., Ltd. Composition and method for prolong survival of transplant and recipient

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
JPH06503344A (ja) 1990-12-06 1994-04-14 ティーセル　サイエンシズ，インコーポレーテッド 可溶性の補体受容体と、補体を抑制しかつ／または免疫活性を抑制する化合物との相乗組成物
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
JP2002502823A (ja) 1998-02-04 2002-01-29 ザ・ジェネラル・ホスピタル・コーポレイション 移植における補刺激遮断および混合キメラ現象
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
AU2001234730A1 (en) * 2000-02-01 2001-08-14 Beth Israel Deaconess Medical Center Method for inhibiting complement activation
DK1325033T3 (da) * 2000-10-10 2010-04-06 Genentech Inc Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
WO2002100148A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
MX342385B (es) 2001-08-17 2016-09-27 Genentech Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b.
CA2473829A1 (en) * 2002-01-22 2003-07-31 Genzyme Corporation Use of tgf-.beta. antagonists to treat or to prevent chronic transplant rejection
US7923010B2 (en) * 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
BRPI0511272A (pt) * 2004-05-17 2007-12-04 Combinatorx Inc métodos e reagentes para o tratamento de distúrbios imunoinflamatórios

Also Published As

Publication number Publication date
ES2528362T3 (es) 2015-02-09
IL179240A (en) 2014-07-31
JP5590624B2 (ja) 2014-09-17
CA2566716C (en) 2014-12-23
US20090028850A1 (en) 2009-01-29
JP2014080438A (ja) 2014-05-08
EP2815767A1 (en) 2014-12-24
IL179240A0 (en) 2007-03-08
AU2005244012C1 (en) 2013-05-02
AU2005244012A1 (en) 2005-11-24
HK1101962A1 (en) 2007-11-02
EP1755674A2 (en) 2007-02-28
WO2005110481A3 (en) 2006-06-22
SI1755674T1 (sl) 2015-04-30
CA2566716A1 (en) 2005-11-24
PL1755674T3 (pl) 2015-05-29
US20190309053A1 (en) 2019-10-10
HK1201758A1 (en) 2015-09-11
HK1222342A1 (zh) 2017-06-30
IL233326A0 (en) 2014-08-31
DK1755674T3 (en) 2015-02-09
EP2338511A2 (en) 2011-06-29
NZ551308A (en) 2009-06-26
JP2013032391A (ja) 2013-02-14
AU2005244012B2 (en) 2011-08-18
JP2007537299A (ja) 2007-12-20
EP3056218A1 (en) 2016-08-17
US20170267751A1 (en) 2017-09-21
WO2005110481A2 (en) 2005-11-24
AU2005244012B9 (en) 2011-11-03
JP5161567B2 (ja) 2013-03-13
EP1755674B1 (en) 2014-11-19
EP2338511A3 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
IL179240A0 (en) Prolongation of survival of an allograft by inhibiting complement activity
IL193623A0 (en) Prolongation of survival of an allograft by inhibiting complement activity
GB2413769B (en) Ureteric stents
EP1939200A4 (en) NEW ADENINE CONNECTION
EP1732566A4 (en) 6-azaindole COMPOUND
EP1798221A4 (en) NITROGENIC HETEROCYCLIC 2-ARYLCARBOXYLENEAMIDE COMPOUND
IL176942A0 (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
AU157195S (en) Watch
EP1961754A4 (en) BICYCLIC HETEROCYCLIC COMPOUND
AU2011236106B2 (en) Prolongation of survival of an allograft by inhibiting complement activity
IL165618A0 (en) Complementary masks
GB2421064B8 (en) Improved chamber
GB0520231D0 (en) Improved chamber
TWI317830B (en) Structure of back cover
GB2426775B (en) Chamber riser
PL369353A1 (pl) Zestaw elementów budowlanych
GB0400811D0 (en) Immunosuppressant
GB0422066D0 (en) Improved chamber
GB0412138D0 (en) Definition of zeroclick
ZA200702621B (en) Containment of produce
GB0407251D0 (en) Anti-tangle aid
PL367647A1 (en) Seat-capsule as means of transport
GB0422950D0 (en) Fairing
AU301442S (en) Loading ledge
GB0406115D0 (en) Vox